Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, ...

Get Instant Summarized Text (Gist) Asthma and antibiotic use at the time of initial endoscopic sinus surgery increase the likelihood of nasal polyp recurrence, necessitating revision surgery. Age ...

Researchers Identify Novel Immune Cells That May Worsen Asthma Jan. 15, 2025 — Researchers have made an important discovery in the field of asthma research, identifying a new population of ...

Apogee plans to advance development of APG777 in expansion indications by initiating a phase 1b trial in asthma in the first half of 2025 ... PD and efficacy against Dupixent in patients with moderate ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

both of which are positioned for indication expansions into severe asthma and COPD. The first biologic to enter the COPD market, Dupixent (dupilumab), has paved the way for competitors ...

Nial Wheate in the past has received funding from the ACT Cancer Council, Tenovus Scotland, Medical Research Scotland, Scottish Crucible, and the Scottish Universities Life Sciences Alliance.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation ...

Dupixent. This blockbuster SNY/REGN drug is currently approved in several countries (including the United States and EU) across multiple type II inflammatory diseases, which include asthma ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite ... from a development and commercial perspective.